Roivant Sciences (NASDAQ: ROIV) — Perfil da empresa, notícias e dados financeiros
Roivant Sciences applies technology to drug development, creating biotech companies to address significant medical challenges efficiently.
Roivant Sciences
Roivant Sciences is a commercial-stage biopharmaceutical company focused on building subsidiary biotech entities, known as Vants, to develop and commercialize targeted medicines and health technologies. Each Vant operates as an agile business dedicated to specific therapeutic areas, including immunology, dermatology, and pulmonary disorders. The company leverages proprietary technology platforms for drug discovery, clinical trial execution, and commercialization. Roivant advances investigational therapies through late-stage clinical trials while pursuing strategic licensing, partnerships, and asset acquisitions to expand its drug pipeline across multiple therapeutic domain areas globally.
Resumo
Operações
Produtos e/ou serviços de Roivant Sciences
- Autoimmune Therapeutics: Development and advancement of targeted biologic and small-molecule candidates for severe autoimmune and inflammatory conditions through specialized subsidiary entities, focusing on clinical evaluation and registrational trials.
- Dermatological Products: Commercialization and ongoing clinical trials for topical therapies and biological treatments targeting chronic dermatological conditions, including psoriasis and inflammatory skin disorders, distributed across primary healthcare and specialty pharmacy channels.
- Pulmonary Therapies: Clinical development of specialized investigational drug candidates aimed at severe respiratory and cardiovascular disorders, utilizing international clinical trial networks to evaluate therapeutic efficacy and patient safety parameters.
- Targeted Oncology Programs: Development of small molecule inhibitors and targeted protein degraders designed to address underlying molecular drivers in oncology, progressing proprietary biopharmaceutical assets through early and late phase clinical trial stages.
- Technology Platforms: Deployment of proprietary computational drug discovery systems, structural biology tools, and advanced data analytics platforms to identify viable therapeutic molecules and streamline clinical trial operational workflows.
- Vant Subsidiary Model: Strategic creation, capital allocation, and governance of focused biopharmaceutical operating subsidiaries, enabling dedicated management teams to advance specialized therapeutic programs, execute clinical trials, and pursue regulatory approvals.
equipe executiva do Roivant Sciences
- Matthew GlineCEO & Director
- Eric VenkerPresident & CEO of Immunovant
- Mayukh SukhatmePresident, Chief Investment Officer & Director
- Frank M. TortiPresident & Vant Chair
- Richard PulikChief Financial Officer
- Jennifer HumesChief Accounting Officer
- Ian RosenblumChief Information Officer
- Sam KaplanGeneral Counsel
- Kelly GraffHead of People
- Alex GasnerExecutive Vice President of Roivant Health
Últimas notícias sobre a Roivant Sciences
Roivant stops CLE study of IMVT-1402
United StatesRoivant reports 56% PH-ILD trial improvement
United StatesRoivant swings to Q4 profit on landmark Moderna litigation settlement
United StatesPriovant Therapeutics launches Phase 2b/3 trial of brepocitinib in lichen planopilaris
United StatesRoivant pivot: FDA fast-tracks dermatomyositis drug as lead asset misses study goals
United States
Principais indicadores financeiros
Resultados divulgados pela Roivant Sciences, em USD.
- Cap. de mercado
- 26,8 bi
- Receita (TTM)
- 7,5 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 8,3 mi | -1,3 bi | -299,8 mi | |
| 29,1 mi | -1,1 bi | -172 mi | |
| 32,7 mi | -824,9 mi | 4,3 bi | |
| 31,5 mi | -809 mi | -1 bi |